Go to content
UR Home

TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial

URN to cite this document:
DOI to cite this document:
Andorfer, Kornelia E. C. ; Zeman, Florian ; Koller, Michael ; Zeller, Judith ; Fischer, René ; Seebauer, Caroline T. ; Vielsmeier, Veronika ; Bohr, Christopher ; Kühnel, Thomas S.
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 14 Nov 2022 14:57


To date, there is no approved local therapeutic agent for the treatment of epistaxis due to hereditary hemorrhagic telangiectasia (HHT). Several case reports suggest the topical use of timolol. This monocentric, prospective, randomized, placebo-controlled, double-blinded, cross-over study investigated whether the effectiveness of the standard treatment with a pulsed diode laser can be increased ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons